PROGRAM
Day 1 3/9
Day 2 3/10
Day 3 3/11
Day 1 3/9
14.30 – 14.45 – Official greetings
14.45 – 14.55 – Introduction and program presentation (Federico BUSSOLINO – Eugenio BRUSA)
OPENING LECTURE
14.55 – 15.20
Haifa SHEN – Methodist Hospital Research Institute, Houston (TX, USA)
Therapeutic Cancer NanoVaccine
A ROLE FOR NANOSCIENCE IN CANCER IMMUNOTHERAPY
Chairs: Gloria BERLIER – Valentina CAUDA
15.20 – 15.45
Jen MORTON – Beatson Institute, CRUK Glasgow Center, Glasgow (UK)
Exploring opportunities for immunotherapy in mouse models of pancreatic cancer
15.45-16:10
Cornelis MELIEF – Department of Immunohematology and Blood Transfusion Leiden University Medical Center, Leiden, (NL)
Combination immunotherapy of Cancer involving Therapeutics vaccination
16.15 – 16.45 – WORKSHOP-MERCKLIFE SCIENCE SRL
16.50 – 17.20 – SHORT TALKS SELECTED AMONG THE SUBMITTED ABSTRACTS
17.25 – 17.50
Anna SCHWENDEMAN – University of Michigan Ann Arbor, USA
HDL Nanodiscs Discovery and Application for Cancer Immunotherapy
17.50 – 18.15
Luisa DE COLA – Istituto di Ricerche Farmacologiche Mario Negri, Milan (I)
Nanocarriers for biomolecules delivery
18.20 – 18.40
VIRTUAL ROOM FOR POSTER PRESENTATION
“JUST THE WOMAN I AM” KEYNOTE LECTURE
18.45 – 19.10
Fiona WATT–Centre for Stem Cells & Regenerative MedicineKing’s College London(UK)
Day 2 3/10
TUMOR MICROENVIRONMENT AND MODELS
Chairs: Valeria CHIONO – Clara MATTU
14.55 – 15.20
David TING – Massachusetts General Hospital – Cancer Center, Boston (MA, USA)
Single Cell Technologies to Define Intratumoral Heterogeneity
15.20 – 15.45
Giulia ADRIANI – Singapore Immunology Network (SIgN) Agency for Science, Technology and Research. Singapore
3D microfluidic model of tumor microenvironment for pre-clinical screening of immunotherapies
SHORT TALKS SELECTED AMONG THE SUBMITTED ABSTRACTS
15.45 – 16.00
Chiara AMBROGIO – Novel approaches to target oncogenic KRAS complex assembly at
the cell membrane
16.00 – 16.15
Gianluca MUCCIOLO – Interleukin 17A depletion: a promising adjuvant strategy to
increase DNA-vaccination efficacy in Pancreatic Ductal Adenocarcinoma treatment
16.15 – 16.45
Kairbaan HODIVALA-DILKE – Barts Cancer Institute London, London (UK)
New routes for vascular modulation
16.45 – 17.10
Joao MANO – Department of Chemistry – University of Aveiro, Aveiro (Portugal)
Soft biomaterials for engineering 3D cancer models
SHORT TALKS SELECTED AMONG THE SUBMITTED ABSTRACTS
17.15 – 17.30
Martina GODEL – P-glycoprotein inhibitors as inducers of immunogenic cell death
17.30 – 17.45
Antonino DI LORENZO – Toll-Like Receptor 2 targeting impairs breast cancer
progression and overcomes resistance to chemotherapy
17.45 – 18.00
Claudia VOENA – The perivascular niche protects ALK+ lymphoma cells from ALK
inhibition through the CCL19/21-CCR7 axis
18.00 – 18.15
Marco CAMPISI – In vitro model of ALK+ Anaplastic Large cells lymphoma and vascular
interactions and prediction of drug efficacy in a 3D microfluidic chip
18.20 – 18.40
VIRTUAL ROOM FOR POSTER PRESENTATION
CELL-BASED IMMUNOTHERAPY
Chairs: Paola CAPPELLO – Marco Agostino DERIU
18.45 – 19.10
Mariolina SALIO – MRC Human Immunology Unit, WIMM, University of Oxford, Oxford (UK)
Harnessing innate-like T cells in cancer immunotherapy
19.10 – 19.35
Samuel MOK – University of Texas-MD Anderson Cancer Center, Houston (TX, USA)
Day 3 3/11
MYELOID CELLS ORCHESTRATE TUMOR RESPONSE
Chair: Federico BUSSOLINO
14.30 – 14.55
Paola ALLAVENA – Humanitas University, Rozzano (I)
Macrophage Reprogramming using TLR-agonist-loaded Polymeric Nanocapsules for the treatment of Cancer
14.55 – 15.20
Dmitry GABRILOVICH – AstraZeneca I Oncology R&D (USA)
Regulation of tumor microenvironment by myeloid-derived suppressor cells
15.20 – 15.30 – AWARDS ASSIGNMENT
15.35 – 16.05 – WORKSHOP-FLUIDIGM
Advancing Breakthroughs in Immuno-Oncology ResearchFrom cell types to tissue: analyse >40 functional and phenotypic markers simultaneously on the Helios and Hyperion™ Imaging System, powered by CyTOF® technology
KEYNOTE LECTURE
16.10 – 16.35
Melody SWARTZ – Pritzker School of Molecular Engineering – University of Chicago (MI, USA)
EMERGING TECHNOLOGIES IN CANCER IMMUNOLOGY
Chairs: Luca PRIMO – Alberto PULIAFITO
16.35 – 17.10
Massimiliano PAGANI – IFOM (The FIRC Institute for Molecular Oncology) e UNIMI, Milan (I)
Organoid models to decipher the interplay between tumor and the immune system
17.10 – 17.35
Giovanni CIRIELLO – Université de Lausanne, Lausanne, (CH)
Cancer Evolutionary Dependencies
17.35 – 18.00
Jérome GALON – Laboratory of Integrative Cancer Immunology, Sorbonne Université, Sorbonne Paris (F)
The immune contexture in the era of cancer immunotherapy
18.00 – 18.25
Henner FARIN – Georg-Speyer-Haus – Institute Tumor Biology and Experimental Therapy, Frankfurt (D)
Patient-derived tumor organoids to model stromal interactions and cell-based immunotherapies
18.25 – 18.40
Concluding Remarks – (Federico BUSSOLINO – Eugenio BRUSA)
Made with CUS Torino
